Cantor Fitzgerald Analysts Lower Earnings Estimates for AXSM

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities research analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for Axsome Therapeutics in a note issued to investors on Wednesday, February 19th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will post earnings per share of ($4.15) for the year, down from their previous forecast of ($2.88). Cantor Fitzgerald has a “Overweight” rating and a $153.00 price target on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.26) per share.

A number of other brokerages have also recently commented on AXSM. William Blair reissued an “outperform” rating on shares of Axsome Therapeutics in a research note on Tuesday. HC Wainwright raised their price objective on Axsome Therapeutics from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Thursday. Robert W. Baird raised their price objective on Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Leerink Partners raised their price objective on Axsome Therapeutics from $110.00 to $150.00 and gave the company an “outperform” rating in a research note on Monday, February 10th. Finally, Truist Financial raised their price objective on Axsome Therapeutics from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Wednesday. One analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $157.64.

Axsome Therapeutics Trading Up 6.7 %

Shares of Axsome Therapeutics stock opened at $137.75 on Friday. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.37 and a current ratio of 2.11. Axsome Therapeutics has a 52 week low of $64.11 and a 52 week high of $139.13. The stock has a 50 day moving average price of $101.29 and a two-hundred day moving average price of $94.84. The stock has a market capitalization of $6.72 billion, a PE ratio of -23.00 and a beta of 1.05.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The business had revenue of $118.77 million during the quarter, compared to analysts’ expectations of $117.83 million.

Institutional Trading of Axsome Therapeutics

Hedge funds have recently made changes to their positions in the company. Raiffeisen Bank International AG purchased a new position in shares of Axsome Therapeutics in the fourth quarter valued at $51,000. Assetmark Inc. purchased a new position in shares of Axsome Therapeutics in the fourth quarter valued at $52,000. R Squared Ltd purchased a new position in shares of Axsome Therapeutics in the fourth quarter valued at $64,000. Aquatic Capital Management LLC purchased a new position in Axsome Therapeutics during the fourth quarter worth about $76,000. Finally, GF Fund Management CO. LTD. bought a new position in Axsome Therapeutics in the 4th quarter worth about $86,000. 81.49% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the business’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 22.40% of the stock is currently owned by corporate insiders.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.